# Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study

> **NCT06310057** · PHASE4 · COMPLETED · sponsor: **Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh** · enrollment: 92 (actual)

## Conditions studied

- Axial Spondyloarthritis

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT06310057
- **Lead sponsor:** Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2024-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06310057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06310057, "Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06310057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*